Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
ESPR on Nasdaq
Shares outstanding
207,440,936
Price per share
$3.70
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
108,004,285
Total reported value
$286,206,908
% of total 13F portfolios
0%
Share change
+9,509,355
Value change
+$32,005,546
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
188
Price from insider filings
$3.67
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Two Seas Capital LP 4.7% -6% $25,836,769 -$543,915 9,749,724 -2.1% Two Seas Capital LP 30 Sep 2025
BB BIOTECH AG 4.9% -2% $12,505,343 -$322,500 9,694,064 -2.5% BB Biotech AG 04 Mar 2025
WASATCH ADVISORS LP 3.5% -33% $18,713,921 -$10,253,910 7,061,857 -35% Wasatch Advisors LP 30 Sep 2025
As of 30 Sep 2025, Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 188 institutional shareholders filing 13F forms. They hold 108,004,285 shares. of 207,440,936 outstanding shares (52%) .

Top 25 institutional shareholders own 45% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 7.2% 14,833,791 +0.82% 0% $39,309,546
VANGUARD GROUP INC 5.8% 12,092,449 +3.2% 0% $32,044,990
Two Seas Capital LP 4.7% 9,749,724 -2.1% 1.6% $25,836,769
WASATCH ADVISORS LP 3.4% 7,061,857 -32% 0.1% $18,713,921
PenderFund Capital Management Ltd. 3.2% 6,676,519 0% 3% $17,692,775
GEODE CAPITAL MANAGEMENT, LLC 2.3% 4,751,396 +3.7% 0% $12,593,578
STATE STREET CORP 2.2% 4,478,834 +19% 0% $11,868,910
MORGAN STANLEY 2% 4,055,626 +284% 0% $10,747,409
Nuveen, LLC 1.8% 3,711,069 +778% 0% $9,834,333
AIGH Capital Management LLC 1.4% 3,000,000 2.8% $7,950,000
MARSHALL WACE, LLP 1.2% 2,521,439 -53% 0.01% $6,681,814
ROYCE & ASSOCIATES LP 1.1% 2,293,488 0.06% $6,077,743
TWO SIGMA INVESTMENTS, LP 1.1% 2,238,618 +22% 0.01% $5,932,338
JANE STREET GROUP, LLC 0.94% 1,953,058 +223% 0.01% $5,175,604
TWO SIGMA ADVISERS, LP 0.92% 1,908,000 -8.9% 0.01% $5,056,200
NORTHERN TRUST CORP 0.89% 1,848,437 +3.6% 0% $4,898,358
GOLDMAN SACHS GROUP INC 0.82% 1,708,807 +114% 0% $4,528,339
CITADEL ADVISORS LLC 0.74% 1,530,364 -34% 0% $4,055,465
Integral Health Asset Management, LLC 0.72% 1,500,000 0.29% $3,975,000
UBS Group AG 0.6% 1,246,310 -19% 0% $3,302,722
MILLENNIUM MANAGEMENT LLC 0.47% 974,856 +115% 0% $2,583,368
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.46% 954,449 +14% 0% $2,529,290
JPMORGAN CHASE & CO 0.46% 945,491 +68% 0% $2,505,552
ROYAL BANK OF CANADA 0.44% 909,232 -22% 0% $2,410,000
RENAISSANCE TECHNOLOGIES LLC 0.37% 773,900 +165% 0% $2,050,835

Institutional Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 92,591 $343,464 -$228,351 370% 7
2025 Q3 108,004,285 $286,206,908 +$32,005,546 265% 188
2025 Q2 98,221,986 $96,659,560 -$25,798,112 98.44% 161
2025 Q1 111,244,473 $160,207,174 -$24,300,638 144% 183
2024 Q4 125,994,195 $277,163,622 +$4,307,915 220% 188
2024 Q3 128,986,677 $212,839,259 -$18,982,525 165% 183
2024 Q2 136,753,565 $303,582,468 +$17,706,627 222% 178
2024 Q1 125,253,145 $335,668,499 +$139,911,069 268% 151
2023 Q4 25,823 $77,211 +$77,211 299% 1
2023 Q3 77,232,361 $75,678,982 -$1,556,692 98% 120
2023 Q2 74,286,796 $103,280,863 -$10,454,820 139% 121
2023 Q1 80,908,311 $128,717,404 -$21,842,715 159% 160
2022 Q4 73,333,669 $456,850,722 +$38,779,483 623% 160
2022 Q3 62,347,432 $417,727,816 +$53,594,117 669.99% 140
2022 Q2 55,224,322 $350,926,562 +$25,248,770 636% 124
2022 Q1 51,686,713 $240,127,422 -$9,961,168 464% 118
2021 Q4 53,249,812 $266,214,585 +$96,706,437 500% 113
2021 Q3 24,622,739 $296,764,346 -$61,226,730 1,204.99% 135
2021 Q2 28,086,300 $594,008,783 -$19,152,622 2,115% 134
2021 Q1 28,485,623 $798,979,191 -$65,409,607 2,804.81% 150
2020 Q4 30,795,273 $800,741,688 -$1,302,301 2,600% 149
2020 Q3 30,504,107 $1,133,787,977 -$33,669,118 3,716.95% 160
2020 Q2 31,971,131 $1,640,361,538 +$122,897,221 5,131% 177
2020 Q1 29,561,868 $915,790,267 +$53,983,094 3,153% 152
2019 Q4 24,856,193 $1,482,254,314 +$46,316,451 5,963% 164
2019 Q3 26,925,611 $986,771,875 -$72,095,862 3,666% 143
2019 Q2 27,281,881 $1,268,985,074 +$246,227,887 4,651.99% 162
2019 Q1 25,894,436 $1,039,608,879 +$20,867,423 4,014.95% 154
2018 Q4 26,707,954 $1,228,495,822 -$65,192,459 4,600% 150
2018 Q3 28,136,044 $1,248,657,559 -$106,930,500 4,436.99% 149
2018 Q2 30,621,720 $1,200,073,249 +$136,915,042 3,919% 148
2018 Q1 26,466,801 $1,914,335,757 +$178,133,242 7,232.97% 183
2017 Q4 24,010,918 $1,580,884,389 +$28,468,726 6,583.94% 162
2017 Q3 24,143,870 $1,210,127,699 +$159,915,543 5,012.03% 148
2017 Q2 20,583,732 $952,626,441 +$139,786,313 4,628% 125
2017 Q1 17,459,050 $616,474,044 +$201,094,983 3,530.98% 115
2016 Q4 14,781,092 $185,056,042 +$1,929,659 1,251.93% 93
2016 Q3 14,324,496 $198,383,330 +$383,807 1,384.92% 96
2016 Q2 14,524,682 $143,510,054 -$26,710,143 988.12% 96
2016 Q1 15,627,549 $263,919,000 -$13,051,607 1,690.97% 101
2015 Q4 16,427,090 $365,743,034 -$11,898,091 2,225.91% 111
2015 Q3 16,611,937 $391,855,349 -$218,093,270 2,359.07% 123
2015 Q2 15,213,226 $1,243,822,346 +$183,691,439 8,175.92% 148
2015 Q1 12,803,656 $1,185,461,048 +$474,729,604 9,260% 142
2014 Q4 7,759,719 $313,997,098 +$167,992,421 4,044% 81
2014 Q3 3,499,852 $85,605,436 +$3,114,456 2,445.98% 48
2014 Q2 5,556,294 $88,004,478 +$1,160,439 1,584% 43
2014 Q1 3,430,722 $51,870,345 +$1,000,640 1,511.88% 39